Moneyta · stock research · no sign-up needed
BNTX
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue
-
Net income
-
as filed with the SEC
Institutions holding
286
+11 last quarter
Overview · BioNTech SE
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT115, which is…
Management team
- Ms. Annemarie Hanekamp · Chief Commercial Officer & Member of Management BoardFind on LinkedIn
- Dr. James Timothy Patrick Ryan Ph.D. · Chief Legal & Business Officer & Member of the Management BoardFind on LinkedIn
- Mr. Ryan Richardson · Chief Strategy Officer, MD & Member of Management BoardFind on LinkedIn
- Dr. Sierk Poetting Ph.D. · MD, COO & Member of Management BoardFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
members see every cardRead the full desk report on BNTX
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.